PHARM (PHARM) News
Follow PHARM (PHARM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Pharming Group Q3 Revenue Rises 21%, Operating Profit Up 89%
Pharming reported preliminary unaudited Q3 revenue of $117.6 million, up 21% year over year, and operating profit of $29.9 million, up 89%. RUCONEST revenue rose 14% to $93.8 million; Joenja revenue grew 58% to $23.8 mil
EQUITY | Oct 27, 2026, 06:12 AM UTC
M
Pharming Group Reports Third-Quarter 2026 Financial Results
Pharming Group reported preliminary, unaudited financial results for the three months ended September 30, 2026. The headline also cites strong revenue growth, Joenja APDS expansion and CVID topline data expected in Novem
EQUITY | Oct 27, 2026, 06:00 AM UTC
M
Pharming Group Reports Q3 2026 Revenue Above Market Expectations
Pharming Group announced preliminary, unaudited revenue for the three months ended September 30, 2026, above market expectations.
EQUITY | Oct 22, 2026, 05:12 AM UTC
M
Pharming Presents Positive Phase II Topline Data for Leniolisib
Pharming presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies.
EQUITY | Oct 14, 2026, 06:01 AM UTC
L
Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction
By Colin KellaherPharming Group has parted ways with its top executive, Fabrice Chouraqui, after a disagreement over the biotechnology company's strategy.Pharming on Tuesday said Chouraqui has stepped down as chief execu
NEWS | Sep 29, 2026, 09:52 AM UTC
L
Pharming Announces Fabrice Chouraqui Will Step Down As CEO And Executive Director Effective Immediately
Pharming Group N.V. EURONEXT:PHARM
NEWS | Sep 29, 2026, 05:04 AM UTC
L
Pharming Group N.V. (PHARM) CEO Steps Down; CCO/CFO Named Interim Co-CEOs
Pharming Group N.V. said CEO and Executive Director Fabrice Chouraqui stepped down effective immediately. CCO Leverne Marsh and CFO Kenneth Lynard were appointed interim co-CEOs while the board begins a search for a perm
NEWS | Sep 29, 2026, 05:01 AM UTC
L
Pharming announces CEO transition
Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and F
NEWS | Sep 29, 2026, 05:00 AM UTC
L
Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja
Pharming Group N.V. EURONEXT:PHARM
REGULATION | Sep 25, 2026, 02:36 PM UTC
L
Pharming Group N.V. (PHARM) Wins FDA Priority Review for Joenja sNDA in Younger Children
FDA accepted Pharming’s sNDA for lower Joenja doses in children 4+ weighing 13—27 kg with APDS and granted Priority Review. PDUFA target action date is Jan 30, 2027.Material DetailsContext by AI AnalystThis is a mid-cycl
REGULATION | Sep 25, 2026, 02:32 PM UTC
L
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Admi
REGULATION | Sep 25, 2026, 02:32 PM UTC
M
HC Wainwright reiterates Buy on Pharming, lifts $37 target
HC Wainwright & Co. reiterated a Buy rating on Pharming with a $37.00 price target, implying upside of 3,736.6% from the Sep 22 close of $0.96.
EQUITY | Sep 22, 2026, 04:17 PM UTC
M
Pharming reports positive Phase II leniolisib topline in PIDs
Pharming said it posted positive topline Phase II data for leniolisib in genetically defined PIDs with immune dysregulation, citing a mean 26.4% spleen volume reduction and no new safety signals. Additional data is plann
EARNINGS | Sep 22, 2026, 05:01 AM UTC
M
Pharming posts positive leniolisib Phase II topline data in PIDs
Pharming said a late-breaking ESID 2026 abstract will highlight positive Phase II topline data for leniolisib in primary immunodeficiencies with immune dysregulation.
EARNINGS | Sep 22, 2026, 05:01 AM UTC
H
PHARM - Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
PHARM - Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
NEWS | Sep 22, 2026, 05:00 AM UTC
H
PHARM: Joenja and RUCONEST fuel growth, with pipeline advances and $375—395M revenue projected for 2026
RUCONEST and Joenja drive strong commercial performance, with Joenja expanding into new indications and geographies. Napazimone advances in pivotal trials for mitochondrial disease. Financial guidance projects $375—395M
EARNINGS | Sep 15, 2026, 06:37 AM UTC
L
Pharming Group N.V. Newly Approved Joenja Doses Are Expected To Be Available In October
Pharming Group N.V. EURONEXT:PHARM
NEWS | Sep 11, 2026, 07:27 PM UTC
H
FDA approves Pharming’s Joenja for children with APDS
Pharming said the FDA approved its supplemental New Drug Application for Joenja® as a first treatment for children with APDS in the U.S.
REGULATION | Sep 11, 2026, 06:01 PM UTC
M
FDA approves Joenja (leniolisib) for APDS in children 4-11
The FDA approved Joenja (leniolisib) as the first treatment for APDS in children aged 4-11.
REGULATION | Sep 11, 2026, 04:08 PM UTC
L
Pharming management to participate in September investor conferences
Pharming Group N.V. said management will participate in investor conferences during September.
EQUITY | Sep 09, 2026, 06:07 AM UTC
H
Pharming launches Joenja (leniolisib) commercially in Japan
Pharming announces the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older.
EQUITY | Aug 13, 2026, 05:00 AM UTC
H
PHARM - Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near
PHARM - Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
EQUITY | Jul 30, 2026, 05:00 AM UTC